Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients

An interferon-free regimen of sofosbuvir plus ribavirin for 24 weeks led to sustained response in three-quarters of previously untreated people with genotype 1 hepatitis C and HIV

Published
05 March 2014
By
Liz Highleyman
AbbVie '3D' combination cures 99% of genotype 1b hepatitis C

A 12-week triple combination of direct-acting antivirals developed by AbbVie cured at least 99% of previously untreated people with genotype 1 hepatitis C infection, Prof. Rajendar Reddy

Published
05 March 2014
By
Keith Alcorn
Simeprevir cures almost 80% of first-time co-infected hepatitis C patients

The next-generation hepatitis C protease inhibitor simeprevir cured almost 80% of previously untreated people with hepatitis C and HIV co-infection when used in combination with pegylated interferon

Published
05 March 2014
By
Keith Alcorn
Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection

The hepatitis C protease inhibitor faldaprevir added to pegylated interferon and ribavirin cured hepatitis C in nearly three-quarters of people with genotype 1 hepatitis C virus

Published
05 March 2014
By
Liz Highleyman
Six-week oral treatment can cure hard-to-treat hepatitis C patients

Interferon- and ribavirin-free treatment using sofosbuvir, ledipasvir and a third direct-acting drug for as little as six weeks can cure most previously untreated people with genotype 1

Published
04 March 2014
By
Liz Highleyman
Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting

Thirty-eight activists from 22 countries joined forces at the first-ever Hepatitis C Virus (HCV) World Community Advisory Board (CAB) to demand equitable access to treatment for hepatitis C virus (HCV) from six multinational pharmaceutical companies. Yet AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Merck, and Roche refused to provide a plan for equitable access to treatment for HCV, a curable infection that kills over 350,000 people each year.

Published
28 February 2014
From
Treatment Action Group
European Medicines Agency advises on compassionate use of a new combination therapy for chronic hepatitis C

Combination of ledipasvir and sofosbuvir to be used in patients in urgent need of therapy to prevent progression of liver disease.

Published
21 February 2014
From
European Medicines Agency
Fighting For Global Access to Hepatitis C Therapies

Battle lines are drawn as the global health community prepares to face off with Big Pharma over the astronomic cost of treatment.

Published
19 February 2014
From
HepMag
Treating HCV -- Is the Price Right?

Are those costs out of line for drugs that promise to cure a notoriously refractory illness in eight or nine cases out of 10? Especially when you consider that HCV is widespread, underdiagnosed, and leads in many cases to serious liver disease and death? Short answer: No one really knows.

Published
19 February 2014
From
Med Page Today
The deadly toll of drug-approval drag

A recent survey of general practitioners by the Canadian Liver Foundation revealed 57 per cent of GPs don't know hepatitis C can be cured despite the fact more than 70 per cent of hep C patients who undergo treatment with available medicines are being cured right now.

Published
14 February 2014
From
Winnipeg Free Press

Filter by country